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Static modela b s t r a c t
Background: This paper compares cost-effectiveness results from two models of maternal immunization
to prevent pertussis in infants in Brazil, one static, one dynamic, to explore when static models are ade-
quate for public health decisions and when the extra effort required by dynamic models is worthwhile.
Methods: We defined two scenarios to explore key differences between static and dynamic models, herd
immunity and time horizon. Scenario 1 evaluates the incremental cost/DALY of maternal acellular pertus-
sis (aP) immunization as routine infant vaccination coverage ranges from low/moderate up to, and above,
the threshold at which herd immunity begins to eliminate pertussis. Scenario 2 compares cost-
effectiveness estimates over the models’ different time horizons. Maternal vaccine prices of $9.55/dose
(base case) and $1/dose were evaluated.
Results: The dynamic model shows that maternal immunization could be cost-saving as well as life-
saving at low levels of infant vaccination coverage. When infant coverage reaches the threshold range
(90–95%), it is expensive: the dynamic model estimates that maternal immunization costs $2 million/
DALY at infant coverage > 95% and maternal vaccine price of $9.55/dose; at $1/dose, cost/DALY is
$200,000. By contrast, the static model estimates costs/DALY only modestly higher at high than at low
infant coverage. When the models’ estimates over their different time horizons are compared at infant
coverage < 90–95%, their projections fall in the same range.
Conclusions: Static models may serve to explore an intervention’s cost-effectiveness against infectious
disease: the direction and principal drivers of change were the same in both models. When, however,
an intervention too small to have significant herd immunity effects itself, such as maternal aP immuniza-
tion, takes place against a background of vaccination in the rest of the population, a dynamic model is
crucial to accurate estimates of cost-effectiveness. This finding is particularly important in the context
of widely varying routine infant vaccination rates globally.
Clinical Trial registry: Clinical Trial registry name and registration number: Not applicable.
 2020 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
The special characteristics of many infectious diseases – trans-
mission from one individual to others, natural immunity afterrecovery from the disease, and the herd immunity that protects
susceptible individuals when other people in the population are
immune – are best captured by dynamic transmission simulation
models. Static models, which are easier, faster, and less costly to
develop and implement, are acceptable in some circumstances,
such as when herd immunity is not an issue [1–4].
Immunization of pregnant women with a single dose of acellu-
lar pertussis (aP) vaccine to prevent pertussis in infants too young
to receive their own vaccine is an intervention for which a static
L.B. Russell et al. Vaccine 39 (2021) 158–166model might be sufficient. The target population, pregnant women,
is a small part of the total population, and the period of immunity
conferred on infants by transplacental antibody transfer is short,
perhaps 6 months at most [5]. Interest in maternal aP immuniza-
tion has grown because, despite decades of routine infant and
childhood vaccination against the disease, pertussis cases began
to increase in many countries between 2005 and 2010, with an
unusual rise in deaths among young infants [6]. Where it is intro-
duced, maternal immunization supplements routine infant vacci-
nation, which can produce significant herd immunity at high
coverage levels. For the whole-cell pertussis vaccine the infant tar-
get vaccination coverage necessary to begin to eliminate pertussis
is thought to be 90%-95% [3].
To inform decisions about investing in maternal aP immuniza-
tion, we compare two models, one static, one dynamic, that were
developed for the same project and with the same purpose – to
explore the public health impacts, costs, and cost-effectiveness of
maternal immunization in low- and middle-income countries
(LMICs) [7]. The static model, previously published, was parame-
terized separately for 3 example LMICs: Brazil, Nigeria, and Bangla-
desh [8]. The dynamic model, reported in this issue [9], was built
with Brazilian data and then partially re-parameterized to evaluate
maternal immunization for Nigeria and Bangladesh. Dynamic
models require much more data – of good quality – and take longer
to build, so it was not efficient to try to fit a separate model for
each country. Instead our strategy was to fit a dynamic model to
one country, in this case Brazil, an upper-middle-income country
with rich surveillance, hospitalization, and mortality data going
back decades, and then use it to project results for others as well.
The purpose of this paper is to take advantage of the two mod-
els, built to evaluate the same intervention, in order to explore
when static models are adequate for good public health decisions
and when the extra effort required by dynamic models is worth-
while. Because the focus is model comparison, not the cost-
effectiveness of maternal immunization in different countries, we
limited the comparisons to Brazil. We defined scenarios for model
comparison that focused on two key differences between static and
dynamic models, herd immunity and time horizon. We hypothe-
sized that the cost-effectiveness of maternal immunization,
although directed at a small portion of the population, depends
on the level of routine infant vaccination and whether that level
is above or below the target vaccination coverage at which the dis-
ease begins to be eliminated.2. Methods
This section describes the models briefly with an emphasis on
common features and key differences. We then describe the sce-
narios defined for the comparisons. A full description of the static
model can be found in [8] and of the dynamic model in [9]. Dia-
grams of the models are included in Appendix A. Base-case param-
eter values for both models and data sources are shown in Table 1.2.1. Static model
The static model, a decision tree built in TreeAge Pro ( TreeAge
Software, Williamstown, Massachusetts), compares two strategies
over an infant’s first year: (1) Maternal aP immunization plus rou-
tine infant whole-cell (wP) vaccination versus (2) Routine infant
wP vaccination alone (Appendix A, Figure A-1). Maternal immu-
nization plus routine infant vaccination branches according to
whether or not the mother receives aP vaccine. After that, both
strategies model the probability that an infant receives whole-
cell-pertussis-containing (wP) vaccine during its first year in each
of five age intervals, defined below. For this paper the static model159in [8] was revised to include inpatient and outpatient treatment
costs.
2.2. Dynamic model
Four variants of a compartmental, age-stratified, dynamic
model that included the entire population, not just mothers and
infants, were tested against monthly data for the years 1999–
2016 [9]. (S = Susceptible, I = Infected/Infectious, R = Recovered.)
o SIR: Those who recover are immune for life.
o SIRS: Immunity wanes and repeat infections can occur.
o SIRS2I2: Immunity wanes, individuals become susceptible again,
and repeat infections can occur. Repeat infections are less seri-
ous so less likely to be reported.
o SIRB2I2: Immunity wanes and repeat infections are less serious so
less likely to be reported. Those susceptible despite vaccination
or previous infection are less susceptible. Exposure to infection
can boost existing immunity.
Calibration was used to select some of the parameter values for
each model variant. The calibration process selected parameter
values that led to the best fit between the projections and the pro-
jection targets, incident pertussis cases and deaths observed over
the period 1999–2016. For the calibration process model parame-
ters were divided into two groups, those that were reasonably cer-
tain and those that were highly uncertain. The reasonably certain
parameters were kept at their base-case values, which came from
the published literature. The highly uncertain parameters were
varied by means of 6 multipliers for contact rates between age
groups, 3 for the reporting rate for outpatient cases, and 3 for the
transmission probabilities per contact. To keep the computations
manageable the multipliers were defined for 3 aggregated age
groups (<1, 1–9, and 10 + years of age). The duration of immunity
conferred by routine vaccination of infants with wP vaccine was
also highly uncertain, so a total of 13 parameters were fitted by cal-
ibration. Akaike’s Information Criterion (AIC) was used to compare
the fit of the four model variants. The third variant, SIRS2I2, was the
best-fitting model (Appendix A, Figure A-2), although the sec-
ond,SIRS, was close and produced similar results. See [9] for more
details about the dynamic model.
2.3. Common features of the models
2.3.1. Strategies evaluated
Both models evaluate the cost-effectiveness of maternal aP
immunization plus routine primary wP infant vaccination on the
schedule used in Brazil (doses recommended at 2, 4, and 6months),
versus routine primary wP infant vaccination alone. Neither model
includes the booster doses at 15 months and 4 years of age that are
part of the recommended Brazilian schedule.
2.3.2. Model outcomes
Both models project changes in deaths from pertussis, deaths
from all causes, pertussis hospitalizations, pertussis outpatient
cases, costs of maternal and infant pertussis vaccination, costs of
pertussis outpatient and inpatient treatment, and cost-
effectiveness under different scenarios.
2.3.3. Data sources
Both models use national data for Brazil, as shown in Table 1.
2.3.4. Age groups
Both models divide the first year of life into 5 age intervals – 0–
1 month, 2–3, 4–5, 6–8, and 9–11 months – to capture the higher
Table 1
Parameter values (calibration range) used for model comparisons.
Symbol Parameter Source Dynamic model value Static model value
Disease parameters
k force of infection Calculated within the model from contact
rates and transmission probabilities per
contact.
None in model
cij contact rate Polish POLYMOD matrix [Appendices 3 and 7
in 9; 10]
Adjusted for Brazilian/Polish
household size and in the
calibration process
None in model
qj transmission probability per
contact
[Appendix 7 in 9, 11] The probabilities in Table A below
were adjusted during the
calibration process
None in model
c 1/infectious period [12] 1/21 days None in model
q1 reporting rate Determined by calibration in dynamic model infants: 8.3%, 1-9y: 7.1%, 10y+: 6.2% 10% for infants
q2 reporting rate among I2 Determined by calibration 40% of the primary case rates None in model
lp pertussis mortality, deaths per
1000 population by age
Brazilian Ministry of Health, National
Mortality Information System (SIM). [13,14]
Brazil, 1999–2016 2007 2014
0–1 m 0.0187 0.1441
2–3 m 0.0167 0.0965
4–5 m 0.0021 0.0186
6–8 m 0.0000 0.0042
9–11 m 0.0000 0.0000
all-cause mortality, deaths per
1000 population by age
Brazilian Ministry of Health, National
Mortality Information System (SIM). [13,14]
Brazil, 1999–2016 0–1 m 72.670 62.118
2–3 m 8.437 6.872
4–5 m 4.458 3.496
6–8 m 3.262 2.281
9–11 m 2.241 1.615
pertussis hospitalizations,
admissions per 1000 population
by age
Brazilian Ministry of Health, National Public
Health System (SUS) National Hospitalization
Database (SIH-SUS) [15,14].
Brazil, 1999–2016 0–1 m 0.694 4.334
2–3 m 0.804 4.666
4–5 m 0.290 1.891
6–8 m 0.069 0.534
9–11 m 0.033 0.204
pertussis outpatient cases (all
confirmed minus hospitalized
confirmed), cases per 1000
population by age
Brazilian Ministry of Health, National
Information System for Notifiable Diseases
(Sinan) [16,14]
Brazil, 1999–2016 0–1 m 0.0375 0.414
2–3 m 0.0794 0.834
4–5 m 0.0375 0.549
6–8 m 0.0194 0.283
9–11 m 0.0138 0.146
population by age for
probabilities
Brazilian Ministry of Health, Department of
Informatics [17]
Brazil, 1999–2016 Brazil 2007 and 2014
DALY weight for pertussis
disability
Global Burden of Disease (GBD) Collaborative
Network [18]
0.051 (0.032–0.074) None in model
Vaccine parameters(see note)
m1 wP vaccine coverage (1st dose) Derived from survey data modeled by Colin
Sanderson using methods reported in [19]. See
Methods.
Brazilian surveys for 1996 and 2007
used to model trend in vaccine
coverage, 1999–2016. See Methods
for projections.
See Methods and Appendix B.
m2 wP vaccine coverage (2nd dose)
m3 wP vaccine coverage (3rd dose)
hC proportion of wP vaccine failure [20] 0.1 (0–0.15) 0.1 (0–0.15)
w1 wP effectiveness (1st dose) [21] 0.68 (95%CI: 0.456–0.811) Same but doses 2 and 3 are
combined: efficacy 95%w2 wP effectiveness (2nd dose) [21] 0.92 (95% CI: 0.847–0.957)
w3 wP effectiveness (3rd dose) [21] 0.99 (95% CI: 0.989–1.000)
mM maternal vaccine coverage Brazilian Ministry of Health, National
Immunization Program [22]
10.9% for 2014***48.4% for
2015***33.8%-70% for 2016–2030
70%
hM proportion of maternal vaccine
failure
[23] 0.1 (0–0.50) 0.1 (0–0.50)
wM maternal vaccine effectiveness [24] 0.91 (95% CI: 0.84–0.95)
rV waning rate Determined by calibration 7.31 years (5–30) Not in model
rM waning rate of maternal vaccine [26] 3 months (2–6)
rR waning rate (natural infection) [25] 20 years (10–50)
Cost parameters (2014 USD)
maternal aP vaccine, dose PAHO Revolving Fund Price List, 2014 [27] 9.55
infant wP vaccine, dose 2.71
wastage rate WHO recommendation 5% (0–15%)
infant vaccine delivery cost [28] 7.60
hospitalization cost –
SURVIVOR, Brazil
Brazilian Ministry of Health, National Public













L.B. Russell et al. Vaccine 39 (2021) 158–166
160
Table 1 (continued)
Symbol Parameter Source Dynamic model value Static model value
65+, 871.36
hospitalization cost – DIED
Brazil
Brazilian Ministry of Health, National Public














outpatient cost, per case (cases
requiring outpatient care only)
Estimated from National Standardized
pertussis treatment guidelines [29] using data






Table A. Transmission probability per contact by age groups estimated at 1956 in England and Wales [11]
Age groups 0y 1-2y 3-4y 5-9y 10-14y 15-24y 25-39y 40-59y 60+y
Transmission probability per contact 8.0  104 9.0  104 8.2  104 8.6  104 4.4  104 1.6  104 1.4  104 0.05  104 1.0  104
Note. Vaccine is assumed to be equally effective against infection and disease.
L.B. Russell et al. Vaccine 39 (2021) 158–166risks of pertussis at younger ages and to model the infant vaccina-
tion schedule in realistic detail. In each infant age interval, follow-
ing receipt of the vaccine (or not) and development (or not) of
protection derived from maternal aP or infant wP vaccination,
the infant can die of pertussis, die of other causes, or survive.
2.3.5. Costs
If the infant dies of pertussis, costs are incurred for treatment. If
the infant survives, costs are incurred for subsequent doses of vac-
cine (if received), and, if the infant contracts pertussis, for pertussis
treatment (hospital or outpatient). The same choices repeat at the
next age interval. Vaccination is modeled by dose (1, 2, or 3) and an
infant who does not receive a scheduled dose in one age interval is
eligible to receive it in the next.
2.4. Key differences between the models
2.4.1. Time horizon
The static model estimates annual outcomes for one year at a
time based on data for that year. The dynamic model uses monthly
data for 1999–2016 to project outcomes for 2017–2030, the base-
case time horizon.
2.4.2. Age groups included
The static model includes only pregnant women and infants (<1
year). The dynamic model includes the entire population, grouped
by age as follows: the same five age groups < 1 year, 12–23months,
2–4 years, and 5–9, 10–14, 15–19, 20–29, 30–39, 40–49, 50–59,
60–69, 70–79 and 80 + years.
2.4.3. Measure of health outcome
The staticmodel projects only years of life, and thus reports cost-
effectiveness as the cost of maternal immunization plus infant vac-
cination, compared with infant vaccination alone, per year of life
gained by maternal immunization. The dynamic model incorpo-
rates the disutility of theweeks that an infantwho contracts pertus-
sis is ill, using disability weights, and thus its cost-effectiveness
ratios are the cost per disability-adjusted life-year (DALY) averted
of maternal immunization plus infant vaccination, compared to161infant vaccination alone. Since, however, the disutility associated
with pertussis lasts only a fewweeks, the primary health gain comes
from lives saved, so the reader can safely interpret the cost-
effectiveness ratios from the two models as comparable.2.5. Scenarios defined for model comparisons
Two scenarios were defined to compare the models. Except as
noted, the scenarios use the base-case parameter values.
Scenario 1. Herd Immunity. The first scenario evaluates maternal
aP immunization against a range of coverage levels for infant vacci-
nation. To represent that rangewe used infant vaccination coverage
rates modeled from national household surveys by the methods in
[19]. Two national surveys were available for Brazil, for 1996 and
2007. Since we wanted to explore the consequences not only of
observed infant coverage levels in Brazil, but also of coverage levels
outside that range, wemade projections for five levels of infant cov-
erage, two based on the Brazilian data and three based on data for
three other LMICs. Brazil’s 2007 data came from a special national
survey. The other four surveys were conducted under the auspices
of the Demographic and Health Surveys (DHS): Brazil 1996, Nigeria
2008, India 2005 and Bangladesh 2011. Nigeria’s 2008 coverage is
the lowest, Brazil’s 2007 coverage and India’s coverage are higher,
but below the 90–95% target coverage range at one year of age. Bra-
zil’s 1996 coverage is in the target range and Bangladesh’s survey
reports rates above 95%. All five coverage levels are evaluated in
the context of Brazil’s experience with pertussis and Brazil’s costs,
so the cost-effectiveness results are interpreted as what would hap-
pen in Brazil at each coverage level.
Colin Sanderson modeled these national survey data to estimate
the proportions of infants who received each of the three recom-
mended doses of wP, by dose and week of age [19, 20a]. The vac-
cination probabilities used in the models – the probabilities that
an infant receives dose 1, 2, or 3 in a given age interval – were
derived from Sanderson’s modeled data using the 2-month spacing
between doses in Brazil’s recommended schedule: dose 1 at
2 months, dose 2 at 4 months, and dose 3 at 6 months. To represent
not just coverage but protection the calculations used data for the
midpoint of each age interval since a few weeks must elapse after a
L.B. Russell et al. Vaccine 39 (2021) 158–166dose is received before the infant has developed immunity. See
Appendix B for details of the vaccination probabilities calculated
for the models.
As infant vaccination coverage was varied, the coverage of
maternal aP vaccine was held at 70% in a given year for the static
model, and throughout the projection period, 2017–2030, for the
dynamic model. This level of maternal coverage was judged to be
reasonable by the Brazilian public health experts on the research
team in light of the coverage already achieved in Brazil, first by
tetanus-diphtheria (Td) immunization for pregnant women, and,
since 2014, by TdaP.
The projections for Scenario 1 were run for two prices of mater-
nal aP vaccine, the base case of $9.55/dose (the 2014 price available
to Brazil through the Pan American Health Organization) and a low
price of $1/dose, such as might be available to low-income coun-
tries. Since maternal immunization has been implemented in Bra-
zil by replacing Td vaccination for pregnant women with TdaP, we
assumed no additional delivery cost associated with aP immuniza-
tion, and since the cost of the tetanus and diphtheria components
is very small we treated the full vaccine price as the cost of aP.
For each level of infant coverage and maternal vaccine price the
dynamic model estimated a single cost-effectiveness ratio for the
projection period, 2017–2030. The static model estimated cost-
effectiveness ratios for two years, 2007, an ordinary endemic year,
and 2014, the peak of the pertussis resurgence in Brazil.
Scenario 2. Time Horizon. As is typical for dynamic models, the
dynamic model estimates an average ratio that represents mater-
nal immunization’s cost-effectiveness over the model’s time hori-
zon for projections (2017–2030 for the base case). The static
model estimates a cost-effectiveness ratio for a single year, based
on the conditions for that year. To explore the effect of the differ-
ences in time horizon between the two models, we held infant vac-
cination coverage at the level of Brazil 2007, and maternal aP
coverage at 70%, for all the projections for this scenario.
The dynamic model then projected cost per DALY averted for
three time horizons: 2017–2025, 2017–2030, and 2017–2045.
The static model projected cost-effectiveness for 2007 and 2014.
A static model can, if populated with data averages, project average
cost-effectiveness over multiple years. To explore the effect of
doing this, the static model was also used to make projections
based on the average probabilities of death from other causes,
death from pertussis, pertussis hospitalization, and pertussis out-
patient cases for the years 1999–2016, the same period on which
the dynamic model was calibrated.2.6. Uncertainty
We calculated 90% confidence intervals around the cost-
effectiveness estimates of the static model using the probabilistic
version of that model. As explained in [8] the probabilistic version
assigns a distribution to each parameter and the model then esti-
mates cost-effectiveness ratios repeatedly, each time using new
sets of values randomly drawn from these distributions. Each
90% interval is based on 1000 such estimates and shows the lower
and upper bounds that, between them, include 90% of the esti-
mates. Following ISPOR-SMDM recommendations [2], the dynamic
model was not made probabilistic and no confidence intervals are
presented for it. Instead we note when its projections fall in the
confidence intervals defined for the static model.3. Results
This section presents cost effectiveness ratios for maternal
immunization for each of the scenarios just described. Costs are
in 2014 US dollars.1623.1. Scenario 1. Herd immunity
The first scenario evaluates the cost-effectiveness of maternal
aP immunization at five different levels of routine infant wP cover-
age. For short, the five levels are referred to as Low (Nigeria 2008),
Moderate1 (Brazil 2007), Moderate2 (India 2005), High (Brazil
1996), and Highest (Bangladesh 2011). The percentages of infants
who had received at least one dose of pertussis vaccine by 26
and 52 weeks of age will help convey the differences among them:
Nigeria (44%, 49%), Brazil 2007 (59%, 90%), India (69%, 72%), Brazil
1996 (89%, 94%), and Bangladesh (96%, 97%). The complete infant
vaccination schedule, shown in Appendix B, is more complex and
reflects doses delivered in each age interval during the first year.
3.1.1. Static model
Maternal immunization saves infant lives, but at the price Brazil
paid for maternal aP vaccine in 2014, $9.55/dose, the additional
costs outweigh the savings in treatment from fewer cases of infant
pertussis (Table 2). The additional cost per life-year increases as
routine infant vaccination coverage rises from Low to Highest. At
2007 pertussis incidence, the cost rises from $12,295/life-year at
Low coverage to $15,467/life-year at the Highest coverage, an
increase of 26%. Cost per life-year is much lower at 2014 pertussis
incidence, even at a maternal vaccine price of $9.55/dose, because
rates of disease and death among infants were substantially higher
in 2014, the peak of the resurgence, than in 2007 (see Table 1). In
2014 the additional cost of maternal immunization was $1,061/
life-year at Low infant coverage and $1,468/life-year at the Highest
infant coverage.
At a maternal vaccine price of $1/dose, cost per life-year is sub-
stantially lower under both 2007 and 2014 pertussis incidence,
even as it again rises with the level of routine infant vaccination
coverage (Table 2). Under 2007 conditions, the cost is less than
$1,000/life-year at all levels of infant vaccination coverage. Under
2014 conditions, maternal immunization is cost-saving at every
level of infant coverage.
The static model was also used to project the cost-effectiveness
of maternal immunization under average conditions for the period
1999–2016, a scenario more like that projected by the dynamic
model. Under average conditions and a maternal vaccine price of
$9.55/dose, the additional cost of maternal immunization is inter-
mediate between the estimates for 2007 and 2014, rising from
$6,563/life-year at Low infant coverage to $8,290 at the Highest
coverage.
3.1.2. Dynamic model
Like the static model, the dynamic model estimates that mater-
nal immunization saves lives, usually at additional cost, although it
can be cost-saving in some conditions, especially when the price of
the maternal vaccine is very low.
The pattern of cost/DALY projected by the dynamic model as
routine infant vaccination coverage rises, however, stands in stark
contrast to that of the static model. At both prices for maternal aP
vaccine, maternal immunization is projected to be cost-saving at
low infant vaccination coverage. But as infant coverage rises cost/
DALY averted rises sharply. With infant coverage at the High and
Highest levels, both of which are high enough to begin to eliminate
the disease from the population, maternal aP immunization
becomes a very expensive way to prevent infant disease and death:
at the Highest level of infant coverage, and a maternal vaccine price
of $9.55/dose, the cost is $2 million per DALY averted (Table 2 and
Fig. 1). At the much lower price of $1/dose, it is $206,487/DALY
(Table 2).
The costs per DALY (or life-year) estimated by the two models
are not close. The estimates from the dynamic model fall outside
the 90% interval for the static model’s estimates (Table 2; CIs are
Table 2
Cost per life-year/DALY (2014$) by type of model, maternal vaccine price, infant vaccine coverage, and time period.








2007 10% 90% 2014 10% 90% 1999–2016 10% 90% 2017–2030
Maternal vaccine price $9.55/dose
Low $12,295 $7,457 $35,506 $1,061 $544 $2,677 $6,563 $3,797 $18,338 -$1,844
Moderate1 $12,469 $6,031 $31,278 $1,084 $278 $2,039 $6,658 $3,322 $16,099 $3,194
Moderate2 $13,140 $6,751 $34,832 $1,172 $442 $2,448 $7,025 $3,502 $19,757 $33,939
High $14,861 $7,364 $41,439 $1,392 $550 $2,956 $7,962 $4,106 $21,601 $1,265,552
Highest $15,467 $9,650 $69,078 $1,468 $906 $3,788 $8,290 $5,353 $37,818 $2,084,122
Maternal vaccine price $1/dose
Low $444 $652 $2,680 $654 $951 $362 $121 $850 $1,006 $2,672
Moderate1 $463 $952 $1,910 $649 $954 $412 $110 $956 $703 $1,966
Moderate2 $535 $576 $2,306 $634 $957 $384 $69 $775 $832 $841
High $721 $566 $2,858 $595 $916 $334 $35 $772 $1,121 $124,425
Highest $787 $153 $5,335 $581 $838 $221 $72 $663 $1,961 $206,487
Note. The static model estimates life-years, the dynamic model disability-adjusted life-years. See Methods.
a. See the first paragraph of the results section and Appendix B for detailed information about these coverage levels.
b. See Methods for an explanation of how the intervals were calculated.
L.B. Russell et al. Vaccine 39 (2021) 158–166not included in Fig. 1 because they would not show up given the
difference in cost-effectiveness ratios depicted there).3.2. Scenario 2. Time Horizon: Average versus Single-Year estimates
The second scenario examines the impact of the different time
horizons used for making estimates in the static and dynamic mod-
els. Table 3 shows estimates for three time periods for each model.
All the estimates are based on infant vaccination coverage at the
level of Brazil 2007 (Moderate1), for the period shown for the static
model and for the entire projection period for the dynamic model,
and a maternal vaccine price of $9.55/dose.3.2.1. Static model
The static model’s estimates reflect pertussis incidence in the
specified year – low incidence in 2007, high incidence in 2014,
and in between those two extremes over the longer period,
1999–2016. Maternal aP immunization adds to costs in all three
periods, but costs the most per life-year saved in 2007, the least
in 2014, and, again, between those two extremes in 1999–2016.
Note that Table 2 also showed the results for 1999–2016 at Brazil’s
2007 infant vaccination coverage (Moderate1). There they showed
how the cost-effectiveness of maternal immunization changes as
infant coverage changes. In Table 3 they emphasize the effect of
looking at a time period longer than one year.3.2.2. Dynamic model
The dynamic model’s projections fall in the same general range
as those from the static model. The dynamic model also shows,
however, that cost per DALY averted declines as the time horizon
of the projection grows longer. The reason for this pattern is that,
at the infant coverage of Brazil 2007, the dynamic model projects
disease under routine infant vaccination alone rising from 2017
to a peak at 2025, then declining slowly but remaining above the
2017 level through 2045. Under maternal immunization plus rou-
tine infant vaccination, the level of disease declines slowly and
steadily from 2017. As a result, the longer time horizons involve
higher average levels of disease under infant vaccination alone,
maternal immunization prevents more disease, and the cost/DALY
declines as the time horizon lengthens through 2045. Over still
longer time horizons cost/DALY might remain steady or even begin
to rise, depending on the level of infant coverage.1634. Discussion
Our models, built to evaluate maternal aP immunization, and
using the same data sources for the same middle-income country,
Brazil, make it possible to explore the well-known differences
between static and dynamic models, not just conceptually but by
comparing their estimates of the cost-effectiveness of maternal
aP immunization.
The main finding of our analysis is that the background effect of
routine infant pertussis vaccination, operating through herd
immunity, is critical to the cost-effectiveness of maternal aP
immunization. The infant vaccination coverage level required to
eliminate pertussis is thought to be in the range 90–95% [3]. Cover-
age at the two highest levels used in our projections are at or above
90–95%. With coverage that high in the model, there is so little per-
tussis circulating in the population that newborns are at almost no
risk, even without maternal immunization. The dynamic model
makes this clear as its estimate of the cost of averting a DALY rises
sharply when infant coverage is in this range, making maternal
immunization very expensive. The static model fails to reflect the
sharp rise in cost per life-year when pertussis drops to such low
levels in the population and shows only a much more modest rise.
The dynamic model also shows maternal aP immunization to be
cost-saving at low infant coverage, even when the static model
does not. When infant coverage is low, the level of pertussis circu-
lating in the population rises and feeds back into a higher risk for
unvaccinated infants.
It is important to note that these conditions do not apply to all
maternal immunization. Maternal immunization to protect infants
against group B streptococcal (GBS) disease, for example, is a case
in which only pregnant women are vaccinated – there is no vacci-
nation of infants or others in the population [31]. In that case Bris-
son’s comment applies [1]: ‘‘If only a small proportion of the
population is immunized (low coverage or targeted vaccination),
or the vaccine does not prevent the circulation of the pathogen
(as occurs with some vaccines), then herd-immunity effects are
negligible. Under such conditions, static and dynamic models pro-
duce similar results.” The results of this analysis show that the
effects of a targeted vaccination program are different when it
takes place against a background of vaccination of the larger pop-
ulation. When an intervention such as maternal acellular pertussis
immunization, which is too small to have significant herd immu-
nity effects itself, takes place against a background of vaccination
Table 3




2007 2014 1999–2016 2017–2025 2017–2030 2017–2045
$12,469 $1,084 $6,658 $6,785 $3,194 $2,511
$6,021–30,397 $312–2,108 $3,251–16,791
Note. The static model estimates life-years, the dynamic model disability-adjusted life-years.
Fig. 1. Effect of Herd Immunity: Cost per life-year saved/DALY averted by type of model, maternal vaccine price, $9.55/dose.
L.B. Russell et al. Vaccine 39 (2021) 158–166in the rest of the population, a dynamic model is crucial to accurate
estimates of its cost-effectiveness.
Given recent modeling guidelines [2] and the trend in the liter-
ature toward dynamic transmission models, is there a role for sta-
tic models when vaccination is widespread in the population? The
rest of the discussion considers that question.1644.1. Advantages of dynamic models
The principal advantage of dynamic models is the purpose for
which they were designed, the ability to simulate the effects of
herd immunity and thus the effects of interventions against infec-
tious disease in one group of the population on the rest of the pop-
L.B. Russell et al. Vaccine 39 (2021) 158–166ulation. As our results have shown, static models can be misleading
when used to evaluate an intervention that, while itself targeted to
a small proportion of the population, takes place against a back-
ground that includes vaccination of large groups of the population.
The results of a static model are, of course, particularly misleading
when background vaccination reaches the level at which herd
immunity becomes a significant factor.
Because they project the pattern of disease incidence over time,
dynamic transmission models can show the path disease incidence
follows as an intervention is introduced and becomes widespread,
while static models cannot. For a longer planning horizon the aver-
ages produced by dynamic models are thus appropriate. For a
shorter horizon, e.g., during an epidemic, static models may be suf-
ficient. Note that static models do not usually incorporate the long-
term duration of immunity conferred by a vaccine, because their
time horizons are short. The very short period of immunity con-
ferred by maternal aP vaccine played a role in this static model,
which focused on the first year of life, but the longer period of
immunity conferred by infant vaccination did not.
Although not demonstrated in this paper, since dynamic models
incorporate all groups in the population they can evaluate inter-
ventions in any group – adolescent boosters, for example – and
their population effects. It also is worth noting that the direct
impact of vaccination on pregnant women was not included in this
dynamic model (nor in the static model).
4.2. Advantages of static models
The principal advantages of static models are that they can be
built more quickly and are easier to use. That makes it possible
to get answers to pressing policy questions more quickly. The static
model reported here was complete and providing results a year
after the project was funded, while the dynamic model took
another year to reach that point. As a result, static models may
serve for preliminary exploration of a situation involving an infec-
tious disease, perhaps while a dynamic model is being developed.
It is worth noting that the direction of change and the principle dri-
vers of change were the same in the static and dynamic models
presented here, although the magnitudes of change were often
very different.
Static models require less data than dynamic models and little
or no use of data that, if not actually unobservable, are unavailable,
such as contact rates and probabilities of transmission of infection
upon contact. In a dynamic model these parameters are often
assigned values through calibration, the process in which a range
of plausible values is tried and the values that produce the best
fit between the model’s projections and the projection targets,
such as disease incidence, are selected. The calibration process is
useful in itself, providing information about the most likely values
for these parameters, but is computationally intensive and time-
consuming.
For the same reason, it is easier to change parameter values in a
static model and to explore the impact of the change. Changing
parameter values that were determined by calibration in a
dynamic model can require re-calibrating the model.
Poor data limit both types of models. Static models can be tai-
lored to the available data more easily than can dynamic models,
which, by their nature, need to simulate the disease process. Static
models can also more easily incorporate probabilistic sensitivity
analysis [2]. While static models can thus more easily explore
the implications of uncertainty about key parameters ([31] is an
example), neither type of model can overcome the problems
caused by seriously inaccurate data. In this project we found, for
example, that administrative data on vaccine coverage overstated
true coverage to such an extent as to show that pertussis should
have been eliminated, leaving no role for maternal immunization;165the problem was not the model’s estimates but the inaccuracy of
the data, and was resolved in this case by locating more accurate
coverage data from household surveys [19].
4.3. Conclusion
Because of the greater ease with which they can be built and
used, static models may continue to play a useful role in the eval-
uation of interventions against infectious diseases, especially inter-
ventions that are small relative to the disease and that do not occur
against a background of other interventions that alter disease
transmission in the population. They can be particularly useful in
providing policymakers with quick and early insights during the
development of the investment case for an intervention. When,
however, the intervention being evaluated will be applied in a sit-
uation where other interventions against the same disease, such as
infant vaccination, are widespread enough to produce herd immu-
nity, dynamic models are needed to produce accurate estimates of
the target intervention’s health outcomes, costs, and cost-
effectiveness. Our results, together with the companion papers in
this issue by Kim [9] and Luz [32] support the recommendation
that dynamic models are needed to evaluate the cost-
effectiveness of interventions that are implemented in these condi-
tions in LMICs.
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